WallStreetZenWallStreetZen

NASDAQ: UTHR
United Therapeutics Corp Stock

$274.67+0.41 (+0.15%)
Updated May 20, 2024
UTHR Price
$274.67
Fair Value Price
$382.43
Market Cap
$12.18B
52 Week Low
$204.44
52 Week High
$275.42
P/E
12.28x
P/B
2.28x
P/S
4.32x
PEG
1.86x
Dividend Yield
N/A
Revenue
$2.50B
Earnings
$1.05B
Gross Margin
88.9%
Operating Margin
57.63%
Profit Margin
42%
Debt to Equity
0.22
Operating Cash Flow
$980M
Beta
0.58
Next Earnings
Jun 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A

UTHR Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how UTHR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

UTHR ($274.67) is undervalued by 28.18% relative to our estimate of its Fair Value price of $382.43 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
UTHR ($274.67) is significantly undervalued by 28.18% relative to our estimate of its Fair Value price of $382.43 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
UTHR ($274.67) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more UTHR due diligence checks available for Premium users.

Be the first to know about important UTHR news, forecast changes, insider trades & much more!

UTHR News

Valuation

UTHR fair value

Fair Value of UTHR stock based on Discounted Cash Flow (DCF)
Price
$274.67
Fair Value
$382.43
Undervalued by
28.18%
UTHR ($274.67) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UTHR ($274.67) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UTHR ($274.67) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

UTHR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
12.28x
Industry
8.16x
Market
31.12x
UTHR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
UTHR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

UTHR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.28x
Industry
6.06x
UTHR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

UTHR price to earnings growth (PEG)

For valuing profitable companies with growth potential
UTHR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

UTHR's financial health

Profit margin

Revenue
$677.7M
Net Income
$306.6M
Profit Margin
45.2%
UTHR's Earnings (EBIT) of $1.44B... subscribe to Premium to read more.
Interest Coverage Financials
UTHR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$6.5B
Liabilities
$1.2B
Debt to equity
0.22
UTHR's short-term assets ($3.25B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UTHR's short-term assets ($3.25B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UTHR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
UTHR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$376.5M
Investing
$735.3M
Financing
-$1.1B
UTHR's operating cash flow ($979.70M)... subscribe to Premium to read more.
Debt Coverage Financials

UTHR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
UTHR$12.18B+0.15%12.28x2.28x
SRPT$12.37B-0.42%319.10x12.87x
INCY$12.84B+0.16%17.17x2.38x
TECH$13.00B-1.56%64.96x6.45x
BMRN$14.63B-0.66%70.69x2.88x

United Therapeutics Stock FAQ

What is United Therapeutics's quote symbol?

(NASDAQ: UTHR) United Therapeutics trades on the NASDAQ under the ticker symbol UTHR. United Therapeutics stock quotes can also be displayed as NASDAQ: UTHR.

If you're new to stock investing, here's how to buy United Therapeutics stock.

What is the 52 week high and low for United Therapeutics (NASDAQ: UTHR)?

(NASDAQ: UTHR) United Therapeutics's 52-week high was $275.42, and its 52-week low was $204.44. It is currently -0.27% from its 52-week high and 34.35% from its 52-week low.

How much is United Therapeutics stock worth today?

(NASDAQ: UTHR) United Therapeutics currently has 44,355,694 outstanding shares. With United Therapeutics stock trading at $274.67 per share, the total value of United Therapeutics stock (market capitalization) is $12.18B.

United Therapeutics stock was originally listed at a price of $6.10 in Jun 17, 1999. If you had invested in United Therapeutics stock at $6.10, your return over the last 24 years would have been 4,406.48%, for an annualized return of 17.2% (not including any dividends or dividend reinvestments).

How much is United Therapeutics's stock price per share?

(NASDAQ: UTHR) United Therapeutics stock price per share is $274.67 today (as of May 20, 2024).

What is United Therapeutics's Market Cap?

(NASDAQ: UTHR) United Therapeutics's market cap is $12.18B, as of May 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

United Therapeutics's market cap is calculated by multiplying UTHR's current stock price of $274.67 by UTHR's total outstanding shares of 44,355,694.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.